Rebus Holdings Inc. (RBSH)
Rebus Holdings Inc. is a biotechnology company focused on developing precision therapeutics for cancer treatment. Through its subsidiaries, the company is engaged in research and development efforts centered on RT-AR001, its lead asset. RT-AR001 is described as an adenosine receptor antagonist being evaluated for tumor infiltration and improved outcomes when delivered directly into a tumor. Rebus Holdings was incorporated in 2003 and is based in Westlake Village, California. Its common stock trades on OTC Markets under the symbol RBSH.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-RBSH
|
—
|
—
|
—
|
—
|
—
|
—
|
Good
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
3.213 K
|
—
|
—
|
—
|
—
|
—
|
—
|